[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"age-related-macular-degeneration-amd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:age-related-macular-degeneration-amd":167},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,45,74,102,128,153,176,199,222,248,273,295,316],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100557714","phase-3-a-study-investigating-subcutaneously-administered-pozelimab-in-combination-with-cemdisiran-or-cemdisiran-alone-in-adult-participants-with-geographic-atrophy-100557714",false,"NCT06541704","A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy","A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration","SIENNA","Key Inclusion Criteria:\n\n1. Study eye with diagnosis of GA of the macula secondary to AMD as described in the protocol\n2. Total GA area in the study eye measuring between ≥2.5 mm\\^2 and ≤17.5 mm\\^2 as described in the protocol\n3. BCVA of 55 letters or better using ETDRS charts (20\u002F80 Snellen equivalent) in the study eye as described in the protocol\n4. Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality fundus imaging in the study eye as described in the protocol\n5. Willing and able to comply with clinic visits and study-related procedures, including completion of the full series of meningococcal vaccinations and pneumococcal vaccination required per protocol\n\nKey Exclusion Criteria:\n\n1. GA in either eye due to causes other than AMD, such as Stargardt disease, cone rod dystrophy or toxic maculopathies like hydroxychloroquine maculopathy\n2. History or current evidence of Macular Neovascularization (MNV) and\u002For exudation or Peripapillary Choroidal Neovascularization (PPCNV) in either eye as described in the protocol\n3. Prior or current Intravitreal (IVT) treatment of any kind for any indication in study eye or fellow eye, except approved or investigational IVT complement inhibitor therapy or anti-VEGF therapy, as long as last dose was ≥6 months prior to randomization\n4. Prior intraocular surgery except cataract extraction or minimally invasive glaucoma surgery in study eye as long as date of these procedures was ≥3 months prior to randomization\n5. Comorbid progressive ocular condition (eg, diabetic retinopathy, macular edema, uncontrolled glaucoma, full thickness macular hole) in study eye that could affect central vision and confound study\n6. Any ophthalmologic condition that reduces the clarity of the media and that, in the opinion of the investigator interferes with ophthalmologic examination of the study eye (e.g., advanced cataract or corneal abnormalities) as described in the protocol\n\n   Systemic Exclusion criteria\n7. History or current use of systemic complement inhibitor therapy within 6 months prior to randomization as described in the protocol\n8. History of solid organ or bone marrow transplantation\n9. Use of chronic (\\>14 days) systemic corticosteroids (oral or parenteral, ≥20 mg oral prednisone or equivalent) within the previous 30 days prior to the first screening visit as described in the protocol\n10. Current or prior use of systemic immunosuppressive therapy other than corticosteroids within 12 months prior to randomization or the likelihood of treatment with any such agent during the study inclusive of the screening period as described in the protocol\n11. Not meeting meningococcal or pneumococcal vaccination requirements as described in the protocol\n12. Carrier of Neisseria meningitidis based on culture collected during screening\n13. Has a hemoglobin A1C ≥ 8.0% during screening as described in the protocol\n\nNOTE: Other protocol-defined Inclusion\u002F Exclusion Criteria apply","ALL","50 Years","85 Years",{"count":21,"type":22},975,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting central vision (what one sees straight ahead).\n\nThe purpose of this study is to evaluate the progression rate of Geographic Atrophy in eyes of patients treated with cemdisiran alone or in combination with pozelimab compared to those treated with placebo.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking the study drug(s)\n* How much study drug(s) are in the blood at different times\n* Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)",[28,29],"Age-related Macular Degeneration (AMD)","Geographic Atrophy (GA)",[31],"GA secondary to AMD","RECRUITING","2026-06-16",{"date":35,"type":36},"2026-06-17","ACTUAL",{"date":38,"type":36},"2024-10-30",{"date":40,"type":22},"2032-05-21",{"name":42,"class":43},"Regeneron Pharmaceuticals","INDUSTRY",217,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100499259","rehabilitating-vision-loss-in-veterans-with-age-related-macular-degeneration-100499259","NCT05780931","Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration","Development of New Approaches to Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration","AMD","Inclusion Criteria:\n\n1. The subject is a Veteran.\n2. The subject is 50 years of age.\n3. The subject has best-corrected visual acuity (BCVA) of 20\u002F40 or worse in each eye, as determined by the standard CNVAMC optometric tests.\n4. The subject has visual field deficit of 10O in either eye as determined by the Octopus 900 perimetry (Haag-Streit Diagnostics, Haag-Streit USA, Mason, OH) administered by CNVAMC. (When the deficit\u002Fs are binocular, they do not necessarily have to be in binocularly corresponding positions.)\n5. The subject has received a formal clinical diagnosis of age-related macular degeneration (AMD) in one or both eyes (binocular AMD does not necessarily have to be in binocularly corresponding positions)7,8,56.\n6. The subject has visual deficit in either eye (wavy lines and\u002For missing\u002Fdarkened areas on the grid) determined by the standard Amsler Grid Test7,8,56.\n7. The subject has not yet started any rehabilitative treatment for AMD-related vision loss.\n8. Both eyes of the subject are otherwise age-appropriately stable, and neither eye has any other visual defects, as determined by the standard CNVAMC ophthalmological examination.\n9. The subject must be able to understand the nature and individual consequences of the study.\n10. The subject must be able to provide signed and dated informed consent before start of any participation in the study procedures.\n11. Women with childbearing potential must test negative for pregnancy using a standard urine test prior to participating in each functional magnetic resonance imaging (fMRI) procedure. (This exclusion criterion is mandated by the Augusta University Institutional Review Board \\[AU IRB\\], which also serves as the IRB of record of the CNVAMC. It is intended as an extra precautionary measure to help ensure the health and safety of this vulnerable population. The proposed study will comply with this requirement.)\n\nExclusion Criteria:\n\n1. According to the patient's VA clinical records, the patient has one or more clinically diagnosed neurological disorder.\n2. According to the patient's VA clinical records, the patient has one or more clinically diagnosed cognitive deficits.\n3. According to the patient's VA clinical records, the patient has been clinically diagnosed with a psychiatric disorder that would make it unduly uncomfortable or otherwise clinically inadvisable for the subject to participate in the study.\n4. According to the patient's VA clinical records, according to the patient, or both, the patient has motor disorder\u002Fs that would make it unduly uncomfortable or otherwise clinically inadvisable for the subject to participate in the study.\n5. According to the patient's VA clinical records, according to the patient, or both, the patient has an MR-incompatible implant and\u002For another condition (e.g., claustrophobia) that would make it inadvisable for the subject to participate in MR imaging or any other study procedure.\n6. The patient does not understand the informed consent information and\u002For the standard study instructions in spoken or written English, and\u002For is unable to follow study instructions. \\[The purpose of this exclusion criterion, required by the AU IRB, is to help ensure that the subjects adequately understand all the information relevant to providing informed consent, as well as the study instructions.\\]\n7. Inability to give informed consent to participate in the study.\n8. Pregnancy, as determined by a standard urine test for pregnancy.\n9. Participation in other study\u002Fstudies including an investigational drug or device during the present study.",{"count":54,"type":22},20,"OBSERVATIONAL","This study will help develop new methods of rehabilitating Veterans with vision loss due to Age-related macular degeneration.",[28],[59,60,61,62,63],"Maculopathy","Macular dystrophy","Drusen","wet AMD","dry AMD","NOT_YET_RECRUITING",{"date":35,"type":36},{"date":67,"type":22},"2026-08-03",{"date":69,"type":22},"2027-05-31",{"name":71,"class":72},"VA Office of Research and Development","FED",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":73},"100330038","medico-economic-evaluation-of-anti-vegf-treatments-in-the-treatment-of-nave-age-related-macular-degeneration-amd-a-model-adapted-to-the-french-context-100330038","NCT03577041","Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context","MEDIAL","Inclusion Criteria:\n\n* Naive neovascular AMD form of retro localization foveal, unilateral or bilateral (one eye per patient will be studied),\n* Patients to be treated with intravitreous injections of Bevacizumab or Ranibizumab or Aflibercept,\n* Patient using effective contraception if he is of childbearing age\n* Patient informed and not having made his opposition to the research,\n* Patient under social security scheme.\n\nExclusion Criteria:\n\n* Previous or current treatment of AMD by intravenous injection of anti-VEGF or surgery dating less than 2 months in the studied eye,\n* Contraindications to the taking of Bevacizumab or Ranibizumab or Aflibercept,\n* Aphakia in the studied eye,\n* Fibrosis or retrofoveolar retinal atrophy of the eye studied,\n* Tearing of the pigment epithelium reaching my macula of the studied eye,\n* Choroidal neovascularization unrelated to AMD,\n* Diabetic retinopathy and \u002F or diabetic maculopathy proven,\n* Glycated hemoglobin greater than 12%,\n* Known hypersensitivity to pharmaceutical agents used,\n* Pregnant or lactating women,\n* Severe active intraocular inflammation, or history autoimmune or idiopathic uveitis,\n* Active or suspected ocular or periocular infection,\n* Intraocular pressure\\> 25mmHg despite two hypotonizing treatments in eye drops,\n* Patient under tutorship or curatorship or private public law.","18 Years","70 Years",{"count":84,"type":22},600,"Age-related macular degeneration (AMD) is the leading cause of blindness after 50 years in industrialized countries, compromising daily activities and reducing quality of life. And whose treatment is one of the first health expenditures. Since September 2015, Bevacizumab, which does not have marketing authorization in AMD, has been given a temporary recommendation for use. Studies in other countries have shown that bevacizumab is cost-effective in the treatment of AMD compared to other anti-VEGF therapies used.",[28],[88,89,90,91],"Neovascular Age-Related Macular Degeneration","Bevacizumab","Cost-Effective","Quality of life","2026-06-12",{"date":94,"type":36},"2026-06-15",{"date":96,"type":36},"2020-01-29",{"date":98,"type":22},"2026-06",{"name":100,"class":101},"Centre Hospitalier Universitaire, Amiens","OTHER",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":73},"100631411","proteomic-biomarker-identification-in-age-related-macular-degeneration-diabetic-retinopathy-and-retinal-detachment-100631411","NCT07500324","Proteomic Biomarker Identification in Age-Related Macular Degeneration, Diabetic Retinopathy and Retinal Detachment","Identification And Validation Of Biomarkers In Ophthalmological Diseases (Age-Related Macular Degeneration, Diabetic Retinopathy And Retinal Detachment) Through Clinical Proteomic Approaches","PRO Project","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability to understand the study procedures and provide written informed consent\n* Willingness and ability to comply with study procedures and visits\n\nFor case subjects:\n\n* Patients with age-related macular degeneration (intermediate or advanced, including geographic atrophy or neovascular AMD)\n* Patients with diabetic retinopathy (non-proliferative or proliferative, with or without diabetic macular edema)\n* Patients undergoing surgery for primary or recurrent retinal detachment\n\nFor control subjects:\n\n* Patients scheduled for cataract surgery with no documented retinal diseases (e.g., AMD, diabetic retinopathy, retinal vascular occlusions, or retinal epithelial disorders)\n* Outpatients with no documented retinal diseases\n* For retinal detachment subgroup: patients undergoing macular surgery (e.g., macular pucker or macular hole) or cataract surgery with attached retina\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Presence of infectious ocular diseases\n* Alterations in the electrophoretic profile of gamma globulins",{"count":111,"type":22},260,[113],"NA","This prospective interventional translational study aims to identify and validate protein biomarkers associated with major ophthalmological diseases, including age-related macular degeneration, diabetic retinopathy (DR), and retinal detachment (RD). A total of approximately 260 participants (cases and controls) will be enrolled at a single center.\n\nBiological samples, including peripheral blood, tears, aqueous humor, vitreous humor, and subretinal fluid, will be collected during routine clinical and surgical procedures. Advanced clinical proteomics approaches will be applied to characterize molecular signatures associated with disease onset, progression, and response to treatment.\n\nThe study seeks to improve the understanding of disease pathophysiology and support the development of novel diagnostic and prognostic biomarkers in ophthalmology.",[116,117,118],"Age-Related Macular Degeneration (AMD)","Diabetic Retinopathy (DR)","Retinal Detachment","2026-05-29",{"date":121,"type":36},"2026-06-02",{"date":123,"type":36},"2024-01-24",{"date":125,"type":22},"2027-01",{"name":127,"class":101},"Fondazione G.B. Bietti, IRCCS",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":73},"100626367","early-treatment-response-in-neovascular-macular-degeneration-with-eylea-8mg-elev8-a-prospective-observational-open-label-study-investigating-the-fluid-dynamics-during-early-response-to-aflibercept-8mg-in-patients-with-exudative-age-related-macular-degeneration-amd-100626367","NCT07434713","EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).","EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8","ELEV8","Inclusion Criteria:\n\n* Diagnosis of subfoveal CNV secondary to wAMD without restriction of lesion size. Active wAMD lesions are characterised by the following:\n* Evidence of SRF and\u002For IRF and\n* area of fibrosis less than 50% of the lesion area. BCVA scores at both screening and baseline must be 23 letters or more as measured by the ETDRS-like charts (or approximate Snellen equivalent to 20\u002F320).\n\nOnly one eye (the study eye) will be treated with study drug. If both eyes are eligible at screening and baseline, the eye with the lower VA will be defined as the study eye. If both eyes are eligible and VA is the same for both eyes, the Investigator will chose the study eye based on clinical judgment.\n\nExclusion Criteria:\n\n* The presence of any one of the following exclusion criteria will lead to exclusion of the participant:\n\n  * Inability to comply with study or follow-up procedures.\n  * Pregnant or nursing (lactating) women.\n  * Women of child-bearing potential, not using or not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the Investigator in individual cases. (Female participants who are surgically sterilised\u002Fhysterectomised, or post-menopausal for longer than 2 years are not considered as being of child-bearing potential.)\n  * Any type of systemic disease or its treatment, in the opinion of the Investigator, including any medical condition (controlled or uncontrolled) that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk.\n  * Stroke or myocardial infarction less than 3 months prior to the date of informed consent signature.\n  * Uncontrolled blood pressure defined as systolic value of \\>160 mmHg or diastolic value of \\>100 mmHg at screening or baseline.\n  * Known hypersensitivity to aflibercept 8mg or any component of the aflibercept formulation.\n  * Prior or current use of any systemic anti-VEGF drugs \\[e.g., bevacizumab (Avastin®)\\]\n  * Current or planned use of systemic medications known to be toxic to the lens, retina or optic nerve, including chloroquine\u002Fhydroxychloroquine (Plaquenil®), deferoxamine, phenothiazines, tamoxifen, and ethambutol.\n  * Use of systemic or intravitreal corticosteroids for at least 30 consecutive days within 3 months prior to the date of informed consent signature.\n  * Use of other investigational drugs within 6 months prior to the date of informed consent signature.\n  * Patient was previously screened for participation in the study and was a screen failure.\n\nExclusion criteria for ocular medical history and conditions:\n\nStudy eye:\n\n* Active periocular or ocular infection or inflammation (e.g., blepharitis, conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) at screening or baseline.\n* Uncontrolled glaucoma (intraocular pressure ≥30 mmHg under treatment or as assessed by the investigator) at screening or baseline.\n* Neovascularization of the iris or neovascular glaucoma at screening or baseline.\n* Inability to obtain SD-OCT images of sufficient quality for analysis.\n* Intraocular surgery (including Yttrium-Aluminum-Garnet capsulotomy) within two months before the date of consent or expected within the next six months after the date of consent.\n* Visually significant cataract, aphakia, pseudoexfoliation, translucent hemorrhage, retinal detachment, diabetic retinopathy, or CNV from a cause other than wAMD at screening or baseline.\n* Structural damage within the central macula in an area of 0.5 disc diameter at screening or baseline that, in the opinion of the investigator, precludes improvement in visual acuity.\n* Subretinal hemorrhage involving the central foveal field with a size of ≥1 disc diameter at screening or baseline.\n* Any prior intraocular treatment with an anti-VEGF medication or intravitreal corticosteroids, or prior treatment with photodynamic therapy (PDT) or other retinal laser treatments before the date of consent.",{"count":137,"type":22},50,"This prospective, observational, open-label study evaluates early treatment response to intravitreal aflibercept 8 mg in patients with exudative age-related macular degeneration. Retinal fluid dynamics assessed by optical coherence tomography and changes in best-corrected visual acuity two months after baseline are analyzed to characterize early treatment outcomes.",[116],[141,142,143],"neovascular macular degeneration","Aflibercept","Eylea","2026-02-19",{"date":146,"type":36},"2026-02-27",{"date":148,"type":36},"2025-07-14",{"date":150,"type":22},"2026-03-27",{"name":152,"class":101},"Insel Gruppe AG, University Hospital Bern",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":73},"100510871","active-amd-study-to-improve-function-in-veterans-100510871","NCT05932069","Active AMD Study to Improve Function in Veterans","The Active AMD Study to Improve Function in Veterans With Age Related Macular Degeneration","Inclusion Criteria:\n\n* The investigators will recruit Veterans with a diagnosis of intermediate stage AMD in at least one eye, aged 65-89, willing and able to cooperate with assessments and interventions.\n* Eligible participants will be quantified \\> 26 on the Montreal Cognitive Assessment (MoCA) to meet the criteria for cognitively intact.\n* Participants will be free from diseases affecting cognition or ability to engage in aerobic exercise (including but not limited to chronic heart, liver, or kidney disease) and from diseases\u002Finjuries directly affecting brain functions (including but not limited to significant closed head injury, open intracranial wounds, stroke, epilepsy, degenerative diseases of the nervous system).\n* Eligible participants will be required to have stable internet access in their home.\n* All subjects will speak English as a primary language and will have graduated high school so that behavioral\u002Fcognitive measures reflect effects of age, AMD, and\u002For aerobic exercise and not the effects of familiarity with English or lack of education.\n\nExclusion Criteria:\n\n* Other, non-AMD, visual impairments. Potential participants with major psychiatric disorder (including but not limited to psychosis, major depression, bipolar disorder) by history will be excluded as well as individuals with current alcohol or substance use disorder.\n* Additionally, individuals with cardiovascular disease and or history of myocardial infarction will not be included.","65 Years","89 Years",{"count":163,"type":22},70,[113],"Age Related Macular Degeneration (AMD) is the leading cause of vision loss among Veterans aged 50 years and older. AMD also adversely affects mortality, physical and cognitive functioning, and activities of daily living. These debilitations negatively impact quality of life for US Veterans. Unfortunately, there are no cures and few treatments. With the increase in the aging Veteran population and the increasing prevalence of AMD, it is imperative to identify and implement strategies to limit the functional burden of AMD. To address this growing challenge, the investigators propose to test the impact of a proven exercise intervention, stationary bicycling (spinning), on visual and non-visual negative health outcomes in AMD. The work in several retinal degeneration mouse models shows that aerobic exercise significantly preserves retinal morphology and function and visual acuity. Even more exciting, the investigators' preliminary work with older Veterans with and without AMD suggests that spin cycling modestly but significantly benefits visual acuity in aged Veterans. Based on this work, the investigators propose to implement a 6-month synchronous, online group spin cycling program for Veterans with AMD, evaluating effects on physical, cognitive, and visual outcomes.",[167],"Age Related Macular Degeneration (AMD)",[167],{"date":170,"type":36},"2026-02-23",{"date":172,"type":36},"2024-03-01",{"date":174,"type":22},"2028-08-31",{"name":71,"class":72},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":183,"maxAge":19,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":73},"100384928","phase-2-long-term-analysis-of-dimethyl-fumarate-to-slow-the-growth-of-areas-of-geographic-atrophy-100384928","NCT04292080","Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy","LADIGAGA","Inclusion Criteria:\n\nAge 55 years of age to 85 years old at the moment of inclusion\n\n* Participant must understand and sign the protocol's informed consent document\n* Participant must have central or non-central geographic atrophy (GA) in at least one eye. GA should be at least 0.75 disk areas (DA) in size but no more than 8 disk areas (DA); approximately 2.54 mm2 is 1 DA. (GA is defined as one or more well-defined, usually more or less circular patches of partial or complete de-pigmentation of the retinal pigment epithelium (RPE), typically with exposure of underlying choroïdal blood vessels. Even if much of the RPE appears to be preserved and large choroïdal vessels are not visible, a round patch of RPE partial de-pigmentation may still be classified as early GA. If a patient has 2 eligible eyes; one eye will be the \"study eye\", graded and evaluated during the whole duration of the study)\n* Participant must have a steady fixation in the study eye in the foveal or parafoveal area and media clear enough for good quality photographs\n* Participant must have visual acuity between 20\u002F20 and 20\u002F200 in the affected eye\n* No suggestive sign of progressive multifocal leukoencephalopathy on brain MR Imaging within 3 months of Tecfidera© treatment Initiation (Only the patients randomized in the TECFIDERA Group will have to go through the MR Imaging)\n* Male participants with female partners capable of conceiving children will be required to use contraception (condom) during the study and for four months after their last experimental treatment caps\n* No documented history of heart disease, absence of family history of sudden death, and QTc duration within normal value (\\\u003C480ms)\n* Participants must be affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Participant is in another interventional investigational study \\\u003C 3 months before inclusion\n* Participant is unable to comply with study procedures or follow-up visits\n* Participant has evidence of ocular disease other than GA in either eye that may confound the outcome of the study (e.g., glaucoma, diabetic retinopathy with 10 or more hemorrhages or micro-aneurysms, uveitis, pseudo-vitelliform macular degeneration, exudative macular degeneration, moderate\u002Fsevere myopia)\n* Participant with antecedent of neo-vascular AMD.\n* Participant has received treatment for exudative AMD, such as macular laser, photodynamic therapy (PDT) or anti-vascular endothelial growth factor (anti-VEGF) therapy intra-vitreal (IVT) injection or of any agent (e.g., triamcinolone) in the study eye within the last four months prior to study enrollment. Vitamin supplementation for AMD is not considered an exclusionary criterion\n* Participant has had a vitrectomy in the study eye\n* Participant is expected to need ocular surgery during the course of the trial\n* Participant has undergone lens removal in the last three months or Yttrium Aluminium Garnet (YAG) laser capsulotomy within the last month\n* Participant is on chemotherapy\n* Participant is on chronic (more than 3 months) immunosuppressive medication administered via ocular or systemic route(s) or is immunosuppressed\n* Participant is on ocular or systemic medications known to be toxic to the lens, retina or optic nerve\n* Participant with a history of malignancy that would compromise the 2-year study survival\n* Participant with a history of ocular herpes simplex virus (HSV)\n* Contra-indications or known hyper-sensibility to Dimethyl Fumarate (Tecfidera™) or experimental treatment excipients\n* Severe active gastrointestinal disease\n* Contra-indications to an MRI using gadolinium such as pace maker, cardiac valve non IRM compatible, cochlear implant or any metallic implant non IRM compatible.\n* Any contraindications to gadolinium including pregnancy, previous allergic reaction, severe kidney disease\n* Any contraindications to aspirin\n* Any screening laboratory value (hematology, serum chemistry or urinalysis) 3 times above normal values or that in the opinion of the Investigator is clinically significant and not suitable for study participation\n* Lymphopenia below normal laboratory values at inclusion.\n* Severe impairment of a vital organ including severe liver and renal impairment\n* Previous organ allograft\n* Patients taking the following non-authorized treatment 3 months prior enrolment: other fumaric acid derivatives (topical occular or systemic), immuno-modulators via ocular or systemic routes (including interferons, sirolimus, chronic use of glucocorticoids) cytotoxic treatments and live attenuated vaccines.(NB: During the experimental treatment period and 3 months thereafter the concomitant use of non-authorized treatment cited above is not allowed in patients randomized in the TEFIDERA group)\n* Patients taking the following non-authorized treatment 3 months prior enrolment: nephrotoxic treatment (aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs (via ocular or systemic routes) or lithium). (NB: During the experimental treatment period and 3 months thereafter the concomitant use of non-authorized nephrotoxic treatment cited above is not allowed in patients randomized in the TEFIDERA group)\n* Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control)\n* History of cancer (other than a non-melanoma skin cancer) diagnosed within the past five years that could be worsened by immunosuppression (In case of history of cancer the risk of immunosuppression must be determined by a specific oncology consultation prior to enrollment.)\n* Ocular or peri-ocular inflammation or infection in either eye\n* Presence of active or inactive toxoplasmosis in any or both eye(s)\n* Presence of active or latent tuberculosis infection\n* Female participants of child bearing potential (those who are not post-menopausal or surgically sterile). Postmenopausal state is 12 months of amenorrhea + high level of FSH if required.\n* Persons under curatorship or guardianship","55 Years",{"count":185,"type":22},90,[187],"PHASE2","The primary objectives of the study are to assess the safety, tolerability and evidence of activity of 12 months oral treatment with TEFIDERA® in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).",[28],"2026-02-02",{"date":192,"type":36},"2026-02-04",{"date":194,"type":36},"2022-02-07",{"date":196,"type":22},"2029-04-07",{"name":198,"class":101},"Assistance Publique - Hôpitaux de Paris",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":4},"100612109","high-throughput-large-model-based-ai-assisted-diagnosis-using-oct-100612109","NCT07249307","High-throughput Large-model-based AI-assisted Diagnosis Using OCT","Study on Key Technologies for High-throughput Large-model-based AI-assisted Diagnosis Using OCT","Inclusion Criteria:\n\n* 1\\. Patients of any age or sex who undergo OCT and\u002For OCT angiography (OCTA) examinations as part of routine clinical care at Peking Union Medical College Hospital.\n\n  2\\. Clinical diagnosis of at least one of the following conditions: Diabetic retinopathy, Branch retinal vein occlusion, Central retinal vein occlusion, Age-related macular degeneration, Pathologic myopia with choroidal neovascularization and Glaucoma with optic nerve damage.\n\n  3\\. Imaging quality sufficient for analysis based on predefined OCT\u002FOCTA quality control criteria.\n\n  4\\. Ability to provide informed consent (for prospective participants), or availability of medical records that meet institutional ethical requirements (for retrospective data).\n\nExclusion Criteria:\n\n\\- 1. Poor-quality OCT\u002FOCTA images that do not meet analysis standards (e.g., severe motion artifacts, media opacity, incomplete scans).\n\n2\\. Patients unable to cooperate with standard ophthalmic imaging procedures. 3. Any condition judged by investigators to preclude accurate imaging evaluation or reliable diagnostic interpretation.",{"count":207,"type":22},2000,"This observational study aims to establish key technologies for high-throughput, large-model-based AI-assisted diagnosis using optical coherence tomography (OCT) and OCT angiography (OCTA). The study will collect real-world OCT\u002FOCTA images and corresponding clinical information from patients with common blinding retinal and optic nerve diseases at Peking Union Medical College Hospital.\n\nA high-throughput diagnostic framework based on large-scale artificial intelligence models will be developed and evaluated. The primary objective is to determine the diagnostic performance of the AI system, including its ability to identify diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, age-related macular degeneration, pathologic myopic choroidal neovascularization, and glaucoma-related optic nerve damage.\n\nThe results of this study are expected to support the development of standardized, efficient, and scalable AI-assisted diagnostic pathways for OCT imaging in clinical practice.",[117,210,116,211,212],"Retinal Vein Occlusion (RVO)","Pathologic Myopia","Glaucoma","2025-11-18",{"date":215,"type":36},"2025-11-25",{"date":217,"type":22},"2025-11-30",{"date":219,"type":22},"2028-12-31",{"name":221,"class":101},"Peking Union Medical College Hospital",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":229,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":73},"100598296","artificial-intelligence-aided-screening-for-patients-with-diabetic-retinopathy-and-age-related-macular-degeneration-in-family-medicine-and-geriatric-medicine-outpatient-clinics-100598296","NCT07069647","Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics","Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* VeriSee AMD is used in non-retinal subspecialty ophthalmology clinics for adults aged 50 and above.\n* VeriSee DR is used in non-retinal subspecialty clinics for diabetic patients aged 20 and above.\n\nExclusion Criteria:\n\n* The patient does not agree to participate in the trial or is unable to provide informed consent.","20 Years",{"count":231,"type":22},4300,[113],"Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are leading causes of vision loss, with rising incidence due to aging populations and increasing diabetes prevalence. However, delayed diagnoses are common due to low disease literacy and lack of dedicated screening tools in internal medicine. This multi-center RCT at National Taiwan University Hospital evaluates the clinical effectiveness and cost-effectiveness of the VeriSee AI-assisted diagnostic software for DR and AMD screening. Participants include adults with diabetes and individuals aged 50 and above meeting AMD screening criteria, randomized to AI-assisted screening with immediate physician explanation or standard physician-only screening. Primary outcomes include detection rates of DR and AMD, ophthalmology referral outcomes, and patient\u002Fphysician satisfaction. Data collection will occur from April 2025 to December 2027. This study aims to provide evidence on the clinical utility of AI-assisted ophthalmic screening in improving early detection, facilitating timely treatment, and reducing severe visual impairment and healthcare burdens in real-world clinical settings.",[116,117],[116,117,236,237,238],"Artificial Intelligence","Randomized Controlled Trial","Fundus Photography","2025-11-16",{"date":241,"type":36},"2025-11-19",{"date":243,"type":36},"2025-10-02",{"date":245,"type":22},"2027-12-31",{"name":247,"class":101},"National Taiwan University Hospital",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":255,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":73},"100599468","pivotal-trial-of-an-automated-ai-based-system-for-early-diagnosis-and-prediction-of-late-age-related-macular-degeneration-100599468","NCT07084883","Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration","Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration in Ophthalmology and Primary Care Settings","Inclusion Criteria:\n\n* Subjects will be recruited if willing and able to comply with clinic visit and study-related procedures, and provide signed informed consent\n\nExclusion Criteria:\n\n* Already diagnosed with AMD, unable to provide informed consent and currently under treatment of retinal disease.",true,{"count":257,"type":22},1076,"The purpose of this study is to perform a pivotal trial of iPredict, an automated AI-based system for early diagnosis and prediction of late AMD in primary care and ophthalmology settings. Patients will be invited to participate in this study by having non-dilated photos of their eyes taken by an FDA approved fundus camera (DRSPlus from Centervue Inc., CA), at their primary care doctor's office or general ophthalmologist office. The photos will then be transmitted securely and analyzed by computer in the cloud (telemedicine features). Sufficient accuracy of the automatic system has been established compared to the ophthalmologist's diagnosis. In this study, we aim to validate the system against the prospectively taken OCT image and color fundus images.",[28],[261,262,263,51],"Screening","Prediction","age-related macular degeneration","2025-08-21",{"date":266,"type":36},"2025-08-28",{"date":268,"type":36},"2024-08-01",{"date":270,"type":22},"2027-07-31",{"name":272,"class":43},"iHealthScreen Inc",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":229,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":281,"conditions":282,"keywords":283,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":294,"locationsCount":73},"100580914","effectiveness-and-cost-effectiveness-evaluations-of-ai-assisted-diagnostic-software-verisee-for-ophthalmic-disease-screening-100580914","NCT06843499","Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening",{"count":279,"type":22},1000,[113],"This study aims to evaluate the effectiveness of an artificial intelligence (AI)-assisted screening system in ophthalmic diagnosis. Using AI-based fundus photography, the system will assist physicians in diagnosing three common eye diseases: age-related macular degeneration and diabetic retinopathy (DR). The AI system will analyze fundus images from participants and rapidly generate detection results for ophthalmologists' reference in making final diagnoses and clinical decisions. The study will assess the clinical benefits of the AI-assisted diagnostic system, providing scientific evidence to enhance the efficiency of ophthalmic disease diagnosis and treatment.",[116,117],[236,284,285,286,287],"imaging analysis","disease diagnosis","macular degeneration","diabetic retinopathy","2025-06-17",{"date":290,"type":36},"2025-06-22",{"date":292,"type":36},"2025-06-02",{"date":245,"type":22},{"name":247,"class":101},{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":314,"locationsCount":73},"100585883","functional-assessments-in-vision-impairment-100585883","NCT06908161","Functional Assessments in Vision Impairment","A Novel Approach for Capturing Real-world Functional Assessment Outcomes in Participants With a Vision Impairment","Inclusion Criteria:\n\n1. Willing to provide signed informed consent.\n2. Be available for study visits.\n3. Willing to comply with study assessments.\n4. In good general health and ambulant.\n5. Aged over 18 years of age.\n6. Have a vision impairment caused by any ocular condition which affects independent mobility.\n7. Agree to allow the research team into their home and local environments.\n8. Participate in assessments in public settings\n\nExclusion Criteria:\n\n1. Significant co-morbidities which prohibit involvement in study visits.\n2. Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.\n3. Cognitive deficiencies, including dementia or progressive neurological disease.\n4. Have a psychiatric condition that, in the investigator's opinion, precludes compliance with the protocol including past or present psychoses and bipolar disorder.\n5. Deafness or significant hearing loss.\n6. Inability to converse in English.",{"count":303,"type":22},45,"The aim of the research project is to validate the use of a novel functional assessment tool designed to document how participants with a vision impairment complete activities of daily living in a real world environment.",[306,117,167,212,307],"Retinitis Pigmentosa (RP)","Retinal Dystrophy","2025-03-26",{"date":310,"type":36},"2025-04-03",{"date":312,"type":22},"2025-04-01",{"date":245,"type":22},{"name":315,"class":101},"Center for Eye Research Australia",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":255,"sex":17,"minAge":81,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":23,"phases":326,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":4},"100580081","phase-1-study-of-jmkx003948-ophthalmic-suspension-in-healthy-participants-100580081","NCT06832657","Study of JMKX003948 Ophthalmic Suspension in Healthy Participants","A Randomized, Double-blind, Placebo-controlled Phase 1 Study of JMKX003948 Ophthalmic Suspension to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Dose(s) in Healthy Participants","Inclusion Criteria:\n\n1. Healthy adult males and\u002For females, 18 to 45 years of age (inclusive) at the date of signed consent form.\n2. Body mass index (BMI) greater than or equal to 18 and less than 32 (kg\u002Fm2) and a minimum body weight of 45 kg.\n3. Able to participate and comply with all study procedures and restrictions, and willing to provide written informed consent to participate in the study.\n4. Women of child-bearing potential and sexually active males willing to use highly effective methods of contraception from screening until 3 months after last dose of study drug. In addition, participants must not donate sperm\u002Fegg for the time period specified above.\n\nExclusion Criteria:\n\n1. History of disease of ocular surface, fundus, central nervous system, psychiatric and psychological condition, cardiovascular system, kidney, liver, digestive system, respiratory system, or metabolic\u002Fendocrine system, or other disease that in the opinion of the Investigator (or medically qualified designee) may make participation unsafe for the participant or interfere with study evaluations.\n2. Any abnormal examination with clinical significance may interfere with study evaluations in opinion of the Investigator (or medically qualified designee).\n3. History of eye trauma or surgery including LASIK\u002FLASEK.\n4. Any corrected visual acuity \\\u003C 20\u002F20, or intraocular pressure ≥ 21 mmHg.\n5. Clinically significant abnormalities on ophthalmic examination that would hinder the assessment of the eye or data collection at the discretion of the Investigator and\u002For ophthalmologist (or medically qualified designee).","45 Years",{"count":325,"type":22},40,[327],"PHASE1","The study is a randomized, double-blind, placebo-controlled, phase 1 study of JMKX003948 Ophthalmic Suspension to evaluate the safety, tolerability and PK of single and multiple ascending doses in healthy participants.\n\nParticipant will be randomized to receive either JMKX003948 Ophthalmic Suspension (1%, 2%, 3% or 5%) or matching placebo (JMKX003948 Ophthalmic Suspension: placebo= 6: 2, N=8 per cohort).\n\nFive cohorts (Cohort 1-5) are planned. Cohorts could also de-escalate to a lower concentration if current formulation was not tolerated (Cohort 1b, 2b and 3b). In case of de-escalation, Cohort 1b and 2b will continue to escalate to Cohort 1c and Cohort 2c, respectively.\n\nParticipants will be admitted to the site on Day -1 after screening (up to 28 days), and remain domiciled until Day 14 for Cohort 1-4, Day 8 for other cohorts.",[116,330],"Diabetic Macular Edema (DME)","2025-02-12",{"date":333,"type":36},"2025-02-18",{"date":335,"type":22},"2025-02",{"date":337,"type":22},"2025-12",{"name":339,"class":43},"Jemincare"]